Results 111 to 120 of about 138,725 (257)

Hepatic heparan sulfate is a master regulator of hepcidin expression and iron homeostasis in human hepatocytes and mice. [PDF]

, 2019
Hepcidin is a liver-derived peptide hormone that controls systemic iron homeostasis. Its expression is regulated by the bone morphogenetic protein 6 (BMP6)/SMAD1/5/8 pathway and by the proinflammatory cytokine interleukin 6 (IL6).
Anower-E-Khuda, Ferdous, Arosio, Paolo, Asperti, Michela, Denardo, Andrea, Esko, Jeffrey D, Gordts, Philip LSM, Gryzik, Magdalena, Poli, Maura, Ruzzenenti, Paola   +8 more
core  

The role of Janus kinase signaling in graft-versus-host disease and graft versus leukemia [PDF]

, 2018
Choi, Jaebok, DiPersio, John F, Schroeder, Mark A, Staser, Karl   +3 more
core   +2 more sources

Real-world comparative effectiveness of bDMARDs and JAK inhibitors in elderly patients with rheumatoid arthritis

, 2022
Jumpei Temmoku, Kiyoshi Migita, Shuhei Yoshida, Haruki Matsumoto, Yuya Fujita, Naoki Matsuoka, Makiko Yashiro‐Furuya, Tomoyuki Asano, Shuzo Sato, Eiji Suzuki, Hiroshi Watanabe, Masayuki Miyata   +11 more
openalex   +1 more source

Fibroblast-Like Synoviocytes Glucose Metabolism as a Therapeutic Target in Rheumatoid Arthritis. [PDF]

, 2019
Metabolomic studies show that rheumatoid arthritis (RA) is associated with metabolic disruption that may be therapeutically targetable. Among them, glucose metabolism and glycolytic intermediaries seem to have an important role in fibroblast-like ...
de Oliveira, Patricia Gnieslaw, Farinon, Mirian, Guma, Monica, Miyamoto, Shigeki, Sanchez-Lopez, Elsa   +4 more
core   +1 more source

Author Correction: Targeting the NF-κB pathway enhances responsiveness of mammary tumors to JAK inhibitors [PDF]

, 2023
Aditi S. Bapat, Christine H. O’Connor, Kathryn L. Schwertfeger   +2 more
openalex   +1 more source

Patient-related factors influencing the effectiveness and safety of Janus Kinase inhibitors in rheumatoid arthritis: a real-world study

Scientific Reports
In real-world scenarios, Janus Kinase (JAK) inhibitors are often offered to "difficult-to-treat" rheumatoid arthritis patients, quite different from those included in randomized controlled trials.
Cristina Martinez-Molina, Ignasi Gich, Cesar Diaz-Torné, Hye S. Park, Anna Feliu, Silvia Vidal, Hèctor Corominas   +6 more
doaj   +1 more source

Effect of JAK inhibitors on release of CXCL9, CXCL10 and CXCL11 from human airway epithelial cells [PDF]

, 2015
Barnes, PJ, Donnelly, LE, Fenwick, PS, Macedo, P   +3 more
core   +1 more source

The JAK inhibitor ruxolitinib reduces inflammation in an ILC3-independent model of innate immune colitis [PDF]

, 2018
A.M. Overstreet, Diana LaTorre, Lisa Abernathy‐Close, Stephen F. Murphy, Lesley Rhee, Antonia Boger, Katie R. Adlaka, Ann Iverson, Danika Bakke, Christopher R. Weber, David L. Boone   +10 more
openalex   +1 more source

The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis. [PDF]

, 2015
ObjectiveTofacitinib is an oral Janus kinase (JAK) inhibitor for the treatment of rheumatoid arthritis (RA). The pathways affected by tofacitinib and the effects on gene expression in situ are unknown.
Boyle, DL, Bradley, J, Firestein, GS, Hodge, J, Kaplan, I, Kavanaugh, A, Krishnaswami, S, Luo, Z, Mandel, D, Mease, P, Rosengren, S, Shurmur, R, Singhal, AK, Soma, K, Wei, N   +14 more
core  

Oral Jak Inhibitor Upadacitinib Use in Treatment of Pemphigus Foliaceus

, 2023
Sophie Guénin, Syed Arbab Shah, Mark Lebwohl   +2 more
openalex   +2 more sources